Carbapenem-Resistant Enterobacteriaceae Infection
Conditions
Brief summary
Severe infections caused by carbapenem-resistant Enterobacterales (CRE) represent a challenge for the clinicians, considering the high mortality rate of these infections. Data regarding the prevalence of CRE, clonal analysis, resistant genes (resistome) and virulence genes (virulome) molecular analyses, and clinical outcomes of infected patients are scarce. Thus, creating a network to Standardize and implement microbiological sourveillance could be crucial to answer this challenge. Our group consisting of the, UOC of Infectious Diseases and UOC of Microbiology (Prof Sanguinetti), the Microbiology Unit of the University of Catania (Prof. Stefania Stefani), the local Infectious Disease Unit (Dr Carmelo Iacobello) the Microbiology Unit of the Magna Graecia'' University (Prof. Giovanni Matera) and the UOC of Infectious and Tropical Diseases UMG Catanzaro Prof Enrico Maria Trecarichi, has already started a project with promising ad interim results on this topic.
Interventions
DIAGNOSTIC_TESTWhole Genome Sequencing (WGS), Sequence Type Analysis (ST)
Whole Genome Sequencing (WGS), Sequence Type Analysis (ST), resistome, viruloma, and phenotypic resistance of CRE
Sponsors
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. age ≥ 18 years; 2. isolation of CRE from a clinically relevant sample considered to be the site of infection: pneumonia, UTI, IAI, spondylodiscitis and BSI. 3. Patients who by clinical practice have received at least one dose of the following drugs from ceftazidime-avibactam, meropenem-vaborbactam, and cefiderocol. 4. Signature of Informed Consent
Exclusion criteria
1. Subjects under 18 years of age 2. absence of CRE infections
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| prevalence of the susceptibility/resistance | 12 months | prevalence of the susceptibility/resistance patterns of ceftazidime- avibactam, meropenem-vaborbactam and cefiderocol in all the CRE isolates |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Prevalence of different Sequence Type Analysis | 12months | To assess the prevalence of different Sequence Type Analysis (ST), resistome and virulome of the collected CRE isolates |
| Odds ratio for the association between multiple factors | 12 months | To assess the odds ratio for the association of the primary endpoint with demographic, clinical, and therapeutic factors |
Countries
Italy
Contacts
Primary ContactCarlo Torti, Prof
Outcome results
None listed